Iimpawu, iiNzuzo kunye neempembelelo zecandelo loLonyango
I-Phosphodiesterase-4-inhibitors (PDE4) njengeDaliresp (i-roflumilast) yintlobo entsha yeziyobisi zesifo esingapheliyo se-pulmonary disease (COPD ) nezinye izifo zamaphaphu. Ezi zi yobisi zisebenza ukukhusela ukuvuvukala kwindlela yokuhamba ngomoya kubantu abachasene nonyango oluqhelekileyo. I-Daliresp (i-roflumilast) yiyona kuphela i-PDE4 inhibitor njengamanje ivunyiwe eMelika.
Indlela iPhosphodiesterase-4-Inhibitors esebenza ngayo
Imithi enjengeDaliresp umsebenzi ngokuthintela imiphumo ye-phosphodiesterase 4, i-enzyme eyenza ukuphula i-molecule ebizwa ngokuthi i-cyclic adenosine monophosphate (ikamp.) Ukwanda kwenyuka kwi -AMPAMP (ngenxa yokuba ayichithwanga yi-phosphodiesterase 4) yenza ukunciphisa ukuvutha imiphunga phakathi kwezinye izinto.
Inqaku eliyiNtloko yeCOPD lukuqhaqhazeka okungapheliyo, kwaye abantu abaneCOPD ne-asthma badla ngokuphindaphindiweyo kwe-PDE4 ekufakeni ukukhupha.
Ngokunciphisa ukuvuvukala, unyango olunjengeDaliresp lunganciphisa ubunqamle obuninzi bokuveliswa kweCOPD, kunye nokunciphisa ukulungiswa kwamanqanawa.
Yintoni i-PDE4 Inhibitors?
Ngokunyusa amazinga e -AMP kunye nokunciphisa ukuvutha, ama-inhibitors e-PDE4 anganciphisa inani le-COPD ukukhushulwa nokuphucula umsebenzi wemiphunga. Ngokukhuphula i -AMP, banokubangela ukuba ezinye ze-bronchodilation.
Kubalulekile ukuba uqaphele ukuba ezi ziyobisi azilungisi imiphunga, zisebenza endaweni yokunciphisa ukuvutha nokukhusela umonakalo omkhulu kunye nokugqithisa kweempawu.
Iimeko apho iDaliresp (Roflumilast) ingasetyenziswa
Iimeko apho iDaliresp zingasetyenziswa ziquka:
- COPD
- Isifuba
- Psoriasis
- I-Psoriatic arthritis
Ziyasetyenziswa Njani?
I-PDE4 inhibitors ezifana neDaliresp isetyenziselwa ukuphucula umsebenzi wamaphaphu kubantu abane-COPD abazinzileyo abanganyangekiyo kunyango oluqhelekileyo.
I-COPD ibonakala inenzuzo kakhulu kubantu abane- bronchitis engapheliyo abahlala bexhatshazwa ngesifo sabo .
Ekubeni la mayeza ayasebenza ekuvufweni okungapheliyo, asebenziswanga ukuhlaselwa ngamandla kweCOPD okanye i-asthma, kodwa kunokuba isilondolozo esingapheliyo sifo.
Ngokungafani ne-bronchodilators engabonakaliyo, iDaliresp yimihla ngemihla, imithi yomlomo efunyenweyo ukuphucula umsebenzi wamaphaphu kwizigulane eziphathwe nge- salmeterol kunye ne- Spiriva (tiotropium.)
Impembelelo ye-PDE4 inhibitors ibonakala iyongezwa nge-corticosteroids.
Imiphumela
Iimpembelelo eziphambili ze-PDE4 inhibitors ziquka isifo sohudo, isicarucu, kunye neentloko. Ingabangela ukulahleka kwesisindo, ngoko isisindo kufuneka sihlolwe ngexesha lotyando kwaye ibangele iimpawu zengqondo kwabanye abantu.
Ukusebenzisana
Ngenxa ye-metabolism yayo nge-cytochrome P-450, ii-inhibitors ze-PDE4 zingaphazamisa (ukwandisa okanye ukunciphisa) ezinye iimichiza zibuye zenzeke ngendlela enjalo, umzekelo, unyango olunjenge-erythromycin, i-cimetidine, iipilisi zokulawula ukuzalwa, imithi yokunqongophala, kunye nokunye.
Kwaziwa kwakhona njenge: PDE4, i-phosphodiesterase-4 inhibitors
Imithombo:
Ferguson, G., kunye neB. Yenza. Ukulawulwa kwezifo ezingapheliyo zokuphazamiseka kwamapulmonary. Isemgangathweno. Ukuhlaziywa 01/21/16.
IMunhall, A., i-Droege, C., Ernst, N., Panos, R., noMnu Zafar. I-Phosphodiesterase 4 inhibitors yokunyanga kwesifo esingapheliyo se-pulmonary disease: ukuhlaziywa kwezidakamizwa zangoku kunye nokuphuhlisa. Iingcamango zengcali kwiiDrams . 2015. 24 (12): 1597-611.
Reid, D., no-N. Pham. I-Roflumilast: unyango olutsha lwe-epidemic obstructive pulmonary disease. Amanqaku e-Pharmacotherapy. 2012. 46 (4): 521-9.
ILayibrari yeSizwe ka-US yamayeza. MedlinePlus. Roflumilast. Ukuhlaziywa ngo-08/15/12. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a611034.html